Peptides

A synthetic peptide for use as a blocking control in assays to test for specificity of DYSFIP1 antibody, catalog no. 70R-4114

A synthetic peptide for use as a blocking control in assays to test for specificity of RPL3 antibody, catalog no. 70R-4713

A synthetic peptide for use as a blocking control in assays to test for specificity of SIRPA antibody, catalog no. 70R-10426

A synthetic peptide for use as a blocking control in assays to test for specificity of CA8 antibody, catalog no. 70R-1122

A synthetic peptide for use as a blocking control in assays to test for specificity of COPS4 antibody, catalog no. 70R-3609

A synthetic peptide for use as a blocking control in assays to test for specificity of MAP3K7IP1 antibody, catalog no. 70R-5775

A synthetic peptide for use as a blocking control in assays to test for specificity of Rad21 antibody, catalog no. 70R-9430

A synthetic peptide for use as a blocking control in assays to test for specificity of PSEN1 antibody, catalog no. 70R-6264

A synthetic peptide for use as a blocking control in assays to test for specificity of C9orf153 antibody, catalog no. 70R-3503

A synthetic peptide for use as a blocking control in assays to test for specificity of RPL27 antibody, catalog no. 70R-2387

A synthetic peptide for use as a blocking control in assays to test for specificity of SLC6A5 antibody, catalog no. 70R-6566

A synthetic peptide for use as a blocking control in assays to test for specificity of PSG6 antibody, catalog no. 70R-3426

A synthetic peptide for use as a blocking control in assays to test for specificity of TRIM34 antibody, catalog no. 70R-8362

A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF488 antibody, catalog no. 70R-8146

A synthetic peptide for use as a blocking control in assays to test for specificity of AGBL5 antibody, catalog no. 70R-3580

A synthetic peptide for use as a blocking control in assays to test for specificity of KCNN2 antibody, catalog no. 70R-1495

A synthetic peptide for use as a blocking control in assays to test for specificity of FBXO4 antibody, catalog no. 70R-2792

A synthetic peptide for use as a blocking control in assays to test for specificity of MICA antibody, catalog no. 70R-1705

A synthetic peptide for use as a blocking control in assays to test for specificity of 2810405K02Rik antibody, catalog no. 70R-9211

A synthetic peptide for use as a blocking control in assays to test for specificity of ATG2A antibody, catalog no. 70R-3823

A synthetic peptide for use as a blocking control in assays to test for specificity of GNL3L antibody, catalog no. 70R-3043

A synthetic peptide for use as a blocking control in assays to test for specificity of LSM6 antibody, catalog no. 70R-4774

A synthetic peptide for use as a blocking control in assays to test for specificity of RP2 antibody, catalog no. 70R-4335

A synthetic peptide for use as a blocking control in assays to test for specificity of PPM1A antibody, catalog no. 70R-5788

A synthetic peptide for use as a blocking control in assays to test for specificity of NUBP1 antibody, catalog no. 70R-4539

A synthetic peptide for use as a blocking control in assays to test for specificity of IER5L antibody, catalog no. 70R-4284

A synthetic peptide for use as a blocking control in assays to test for specificity of MATN3 antibody, catalog no. 70R-5334

A synthetic peptide for use as a blocking control in assays to test for specificity of HSPA1A antibody, catalog no. 70R-1244

A synthetic peptide for use as a blocking control in assays to test for specificity of MRPL48 antibody, catalog no. 70R-2434

A synthetic peptide for use as a blocking control in assays to test for specificity of PLAC9 antibody, catalog no. 70R-3519

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP11B2 antibody, catalog no. 70R-3457

A synthetic peptide for use as a blocking control in assays to test for specificity of PHF19 antibody, catalog no. 70R-8878

A synthetic peptide for use as a blocking control in assays to test for specificity of FRK antibody, catalog no. 70R-5664

A synthetic peptide for use as a blocking control in assays to test for specificity of APCS antibody, catalog no. 70R-1655

A synthetic peptide for use as a blocking control in assays to test for specificity of SOCS7 antibody, catalog no. 70R-5835

A synthetic peptide for use as a blocking control in assays to test for specificity of GREM2 antibody, catalog no. 70R-3740

A synthetic peptide for use as a blocking control in assays to test for specificity of GTPBP9 antibody, catalog no. 70R-4946

A synthetic peptide for use as a blocking control in assays to test for specificity of GUSB antibody, catalog no. 70R-1858

A synthetic peptide for use as a blocking control in assays to test for specificity of NRD1 antibody, catalog no. 70R-3037

A synthetic peptide for use as a blocking control in assays to test for specificity of GABARAP antibody, catalog no. 70R-9625

A synthetic peptide for use as a blocking control in assays to test for specificity of PURB antibody, catalog no. 70R-4611

Blocker of Kv4.2 and Kv4.3 channels

CMV pp65 protein:
CMV pp65 (113-121) is an epitope of the main component of the enveloped subviral particle pp65 (phosphoprotein ppUL83) of Cytomegalovirus, member of herpes virus group. CMV pp65 antigens are used as target for the diagnosis of concomitant CMV end-organ disease. CMV specific cytotoxic T lymphocyte response is highly focused to pp65 in the context of HLA-A24:02.
Applications of CMV pp65 (113-121):
CMV pp65 (113-121) is used to stimulate peptide-specific CTL response and to analyze interferon γ production by flow cytometry and ELISPOT assay. CMV pp65 (113-121) contains HLA-A24 binding site and elicits CMV pp65 (113-121)-specific CTL in PBMCs which recognize pp65 expressed on CMV-infected fibroblast of HLA-A24 positive patients. CMV pp65 (113-121) might be implicated in improvement of immunotherapeutic strategies for efficient vaccine development against HCMV.

MBP (Myelin Basic Protein – UniProtKB – P04370) is a major constituent of the myelin in nerves. This protein permits the maintain of the myelin structure. MBP contains various epitopes implicated in Multiple Sclerosis.
MBP (84-97) induces EAE

Scrambled LL-37 has the same peptide sequence as LL-37 but loses helixforming property.
Scrambled LL-37 can be used as a negative control of LL-37 studies.

Fluorescent TAT peptide.

Blocker of P/Q-type calcium channel (Cav2.1)

ASIC1a/1b agonist

Slowing of Nav1.2, Nav1.4 and Nav1.7 channels' inactivation

Biotin-MAGE-A1 (278-286) is the N-ter biotinylated version of MAGE-A1 (278-286). Biotin-MAGE-A1 (278-286) can be used in the analysis of antigen-specific T cells. MAGE-A1 protein:
MAGE-A1 (278-286) is an epitope of Melanoma Antigen Gene A1 expressed by tumors of different histological types such as on the surface of breast carcinoma cell and is a Cancer/Testis Antigens (CTA). MAGE-A1 is a tumor antigen expressed in 40% of melanoma and contains epitope for binding HLA-A*02:01 molecules and that are recognized by cytotoxic T cells.
Applications of MAGE-A1 (278-286):
MAGE-A1 (278-286) is used to stimulate specific cytotoxic T cells in PBMCs and to analyze by ELISPOT peptide epitope specificity and cytokine production like IFN-γ. Immunogenicity of MAGE-A1 (278-286) raised the possibility of developing anticancer immunotherapies or vaccinations. MAGE-A1 is also expressed in lung adenocarcinoma and studies suggest that MAGE-A1 may serve to develop Chimeric Antigen Receptor (CAR) T cell therapy using lentiviral vector and show an encouraging tumor-inhibitory efficacy.
Sequence: Biotin-KVLEYVIKV

Selective blocker of muscular nACh receptors

Human beta-defensin-2 (hBD-2), also known as skin-antimicrobial peptide 1 (SAP1) is a cysteine-rich cationic antimicrobial peptide of 41 amino acids. It was originally isolated from skin cells of psoriasis patients. hBD-2, which belongs to the defensin family, is implicated in the innate immunity thanks to its antimicrobial activity. Thus, β-defensins can play a role at the cutaneous level by limiting the use of antibiotics in severe burns and disease like psoriasis. Moreover, at the pulmonary level, defensins might be involved in the resorption of the infection in cases of cystic fibrosis.
hBD-2 is produced after stimulation of epithelial cells following their contact with some organisms like Gram-negative bacteria and Candida Albicans, fungus or cytokines such as TNF-alpha and IL-1 beta. This antimicrobial activity was shown to be microbicidal at concentrations greater than 1 µM and was lethal for E.Coli and pseudomonas (LD90 : 10 mg/mL) and Candida Albicans (LD90 : 25 mg/mL). Besides its antimicrobial activity, hBD-2 also exhibits proinflammatory properties as chemoattractants for memory T-cells, immature dendritic cells, mast cells and neutrophils.
hBD-2 has also demonstrated inhibitory activity of the voltage-gated potassium channel Kv1.3 at picomolar concentration. Kv1.3 are overexpressed by T-cells in case of autoimmune disorders.

Biotin-SARS-CoV-2 Spike RBM 480-496 (Biotin-LC) peptide is the biotinylated version of SARS-CoV-2 Spike RBM 480-496 peptide. SARS-CoV-2 Spike RBM 480-496 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Motif (RBM). Biotin-SARS-CoV-2 Spike RBM 480-496 peptide is useful for vaccine development and for structure-activity relationship studies
SARS-CoV-2 Spike (S) glycoprotein
Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.
With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane.
SARS-CoV-2 Spike RBM:
The receptor-binding domain in SARS-CoV-2 Spike protein contains a receptor-binding motif RBM. SARS-CoV-2 Spike RBM is the main functional motif in RBD and allows contacts between the S protein and the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.

Protirelin – Thyrotropin-releasing hormone (TRH) (CAS: 24305-27-9)

SB-peptide offers the scrambled version of MAGE-A p248V9. RQYVELPYV can be used as a negative control of MAGE-A p248V9 studies.
SB-peptide offers also MAGE-A p248V9 (see section MAGE-A p248V9)).
MAGE-A protein:
MAGE-A p248V9, also kwon as multi-MAGE-A (YLEYRQVPV) is an epitope of Melanoma Antigen Gene expressed by tumors of different histological types and is a Cancer/Testis Antigens (CTA). Type of MAGE-A expressed in tumors cells varies according to the type of tumor. Targeting epitopes shared by all MAGE-A antigens would be interest in immunotherapy against a broad spectrum of cancers.
Applications of MAGE-A p248V9 (multi-MAGE-A) :
MAGE-A p248V9 is very useful because it could generate an HLA-A*02:01-restricted CTL response and shared by MAGE-A1,-A2,-A3,-A4,-A6,-A10 and -A12. MAGE-A p248V9 is used to stimulate specific cytotoxic T lymphocytes (CTL) in PBMCs and then to analyze CTL response especially the cytokine production by ELISPOT assay.
Sequence : RQYVELPYV

Hydrogels are a class of materials that are promising candidates for use in soft tissue and bone engineering. Hydrogels have a high water content, suitable viscoelasticity and biocompatibility.
Using hydrogel can help for biomedical applications such as tissue engineering, encapsulation methods for cells and biomolecules, drug delivery or some injectable delivery vehicles for therapeutics.
However, hydrogels are mainly used for their antimicrobial properties which are due to the surface of the hydrogel, having the capacity to disrupt negatively-charged bacterial membrane via electrostatic interactions. Antimicrobial activities of hydrogels were shown against gram-positive bacteria such as S.Aureus and gram-negative bacteria like E.Coli.
The main interest of employing hydrogels is its biocompatibility in vitro and in vivo which permits to hydrogel to be able to perform an appropriate host response in a specific situation.
It also seems that the antimicrobial peptide-based hydrogels are very effective against biofilm adhesion likely due to the physical mode of action involving bacterial membrane disruption.
Max 1 is the first MAX peptide described, a 20-amino acid peptide designed to understand peptide intramolecular folding. Max 1 is useful for making hydrogels owing to its ability to change its structural conformation according to environmental changes.
Max 1 stays unfolded and soluble in a low ionic strength aqueous solution (10 mM NaCl) at neutral pH however with a high salt concentration (150 mM NaCl) or a higher pH, Max 1 folds into an amphiphilic β-hairpin conformation that can self-assembles to form a network of fibrils that conducts to the formation of a hydrogel hairpin.

Selective blocker of N-type calcium channels

Selective blocker of Kv3.4 and potent Nav1.7 activator

SB-peptide offers the scrambled version of MAGE-A1 (278-286). ELIVKVYKV can be used as a negative control of MAGE-A1 (278-286) studies.
SB-peptide offers also MAGE-A1 (278-286) (see section MAGE-A1 (278-286)).
MAGE-A1 protein:
MAGE-A1 (278-286) is an epitope of Melanoma Antigen Gene A1 expressed by tumors of different histological types such as on the surface of breast carcinoma cell and is a Cancer/Testis Antigens (CTA). MAGE-A1 is a tumor antigen expressed in 40% of melanoma and contains epitope for binding HLA-A*02:01 molecules and that are recognized by cytotoxic T cells.
Applications of MAGE-A1 (278-286):
MAGE-A1 (278-286) is used to stimulate specific cytotoxic T cells in PBMCs and to analyze by ELISPOT peptide epitope specificity and cytokine production like IFN-γ. Immunogenicity of MAGE-A1 (278-286) raised the possibility of developing anticancer immunotherapies or vaccinations. MAGE-A1 is also expressed in lung adenocarcinoma and studies suggest that MAGE-A1 may serve to develop Chimeric Antigen Receptor (CAR) T cell therapy using lentiviral vector and show an encouraging tumor-inhibitory efficacy.
Sequence : ELIVKVYKV

α9α10 and α7 nAChRs channels discrimination

Bombesin (BBN) is a 14-amino acid neuropeptide originally isolated from the skin of Bombina bombina. The bombesin-related family comprises three other peptides, the amphibian homologs alytesin and Neuromedin C (NMC), and the mammalian peptide named Gastrin-Releasing Peptide (GRP). Bombesin and bombesin-related peptides are characterized by a region of homology at the carboxy-terminus ending with Gly-His-Leu-Met-NH2, in which resides their biological activity.
Bombesin is active in mammals and affects a broad range of biological functions including smooth muscle contraction, cell growth, blood pressure, plasma glucose, as well as gastric secretions2. These effects are mediated by the interaction of Bombesin peptide with G protein-coupled receptors (GPCRs) called bombesin receptors that are well represented in the gastrointestinal tract and in the central nervous system (CNS).
Bombesin peptide is a potent natural agonist of the mammalian Gastrin Releasing Peptide Receptor (GRPR) also know as bombesin receptor 2 (BB2), whose endogenous ligand is the Gastrin Releasing Peptide (GRP). Bombesin has demonstrated a high affinity for human Gastrin-Releasing Peptide Receptors (hGRPR) in both human cells containing native GRP receptors and murine cells stably expressing human GRP receptors (IC50 = 0.17±0.01 nM and 0.07 ± 0.01 nM, respectively).There is increased interest in targeting the bombesin receptors to explore their roles in pathophysiological processes, and for diagnostic imaging of human cancers over-expressing Gastrin-Releasing Peptide Receptors (GRPR), such as prostate, breast, and small-cell lung carcinoma. Bombesin peptide is investigated as targeting peptide to deliver radiotracers and therapeutic agents into tumors. Moreover, many synthetic agonist analogs of the biologically active COOH terminus of bombesin-related peptides have been synthesized to develop more metabolically stable and selective ligands for Bombesin receptors.

The Nucleocapsid Protein (N-protein), also called coronavirus nucleocapsid (N), is the most abundant protein in coronavirus. It is a structural protein that forms complexes with genomic RNA, interacts with the viral membrane protein during virion assembly and plays a critical role in enhancing the efficiency of virus transcription and assembly.

Secondary SIL peptide for Dupilimab detection and quantification

Peptide named cardiac myosin heavy chain (Myhc)-α 334–352 induces autoimmune myocarditis in mice bearing H-2 allele IAk.